Synthetic Opioid key responses
- Mapping evidence-based key responses to synthetic opioids and their implementation strategies
- Field-tested Toolkit with seven implementation guides
The Top Three Alternative Treatments for Hepatitis C
For those who are not able to conquer the Hepatitis C virus with combination therapy, discover three holistic approaches that can help improve your treatment odds and/or stave off liver damage.
Decline in incidence of HIV and hepatitis C virusinfection among injecting drug users in Amsterdam;evidence for harm reduction?
In Amsterdam, HIV prevalence has nearly halved among injecting drug users (IDU) since 1990. Hepatitis C virus (HCV) prevalence also declined; HIV and HCV incidence dropped to nearly zero. We examined possible explanations for these time trends, among which the implementation of harm reduction measures aimed at reducing the risk behaviour of IDU.
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
Up-to-date evidence about levels and trends in disease and injury incidence, prevalence, and years lived with disability (YLDs) is an essential input into global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013), we estimated these quantities for acute and chronic diseases and injuries for 188 countries between 1990 and 2013.
Estimates on HCV Disease Burden Worldwide - filling the gaps
As resources are limited, solid data to estimate the disease burden caused by HCV are urgently needed. Epidemiology data and disease burden analyses for 16 countries are presented.
Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis
There are concerns around poorer response to direct-acting antiviral (DAA) therapy for hepatitis C virus infection among people who use drugs. This systematic review assessed DAA treatment outcomes among people with recent drug use and those receiving opioid substitution therapy.
Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs
Peer-supported and strongly integrated, comprehensive HCV care will help PWID reach high uptake and adherence to c
Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia. Tamar Kikvidze et al.
Peer support can enable patient engagement with healthcare services, particularly for marginalised populations. In this randomised controlled trial, the efficacy of a peer support intervention at promoting successful engagement with clinical services for chronic hepatitis C was assessed.
Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. Carriere MP et al.
Coffee has anti-inflammatory and hepatoprotective properties. In the general population, drinking ≥3 cups of coffee/day has been associated with a 14% reduction in the risk of all-cause mortality. The aim of this study was to investigate the relationship between coffee consumption and the risk of allcause mortality in patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Methods: ANRS CO13 HEPAVIH is an ongoing Fre
Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention, R. Stagg et. al.
Peer support can enable patient engagement with healthcare services, particularly for marginalised populations. In this randomised controlled trial, the efficacy of a peer support intervention at promoting successful engagement with clinical services for chronic hepatitis C was assessed.
Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Larney, et. Al
Coverage of HIV and HCV prevention interventions for PWID remains poor and is likely to be insufficient to effectively prevent HIV and HCV transmission. Scaling up of interventions for PWID remains a crucial priority for halting the HIV and HCV epidemics.
